Vesely D L, Sallman A L, Bayliss J M
Department of Medicine, University of South Florida Health Science Center, James A. Haley Veterans Medical Center, Tampa 33612.
Ren Physiol Biochem. 1992 Jan-Feb;15(1):23-32. doi: 10.1159/000173438.
Two peptides with natriuretic and diuretic properties consisting of amino acids (a.a.) 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF), which normally circulates in humans and animals, were investigated to determine if they have specific binding sites on distal nephrons, proximal tubules, renal cortical and medullary membranes. Competitive binding experiments revealed that proANFs 1-30, 31-67, and 99-126 (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants (Kd) for proANFs 1-30, 31-67, and 99-126 binding to renal cortical membranes were similar at 9.8, 5.1, and 4.7 nM, respectively. In renal medullary membranes, on the other hand, proANF1-30 (Kd = 3.7 nM) and proANF31-67 (Kd = 2.9 nM) had a 10-fold higher binding affinity than ANF (Kd = 56 nM). All three peptides had very weak binding to proximal tubules with the respective Kds for proANF1-30, proANF31-67, and ANF of 892, 789, and 550 nM indicating a 50- to 100-fold less affinity for their binding sites in proximal tubules than in distal nephrons (Kds of 4.9, 5.3, and 11 nM, respectively). Each peptide bound to the respective kidney membranes or tubules between 10(-8) and 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7) M. Neither insulin, growth hormone, nor adrenocorticotrophic hormone competitively inhibited the binding of proANF 1-30, proANF 31-67 or ANF. These results suggest that proANF 1-30 and proANF31-67 do not work through the ANF receptor but rather have their own separate and distinct receptors to mediate their diuretic and natriuretic effects in the kidney.
对两种具有利钠和利尿特性的肽进行了研究,这两种肽由心房利钠因子原激素(proANF)98个氨基酸的N端的1 - 30和31 - 67位氨基酸组成,它们通常在人和动物体内循环,目的是确定它们在远曲小管、近端小管、肾皮质和髓质膜上是否有特异性结合位点。竞争性结合实验表明,proANF的1 - 30、31 - 67和99 - 126(即C端;ANF)各自具有特异性且独立的结合位点。proANF的1 - 30、31 - 67和99 - 126与肾皮质膜结合的解离常数(Kd)分别相似,为9.8、5.1和4.7 nM。另一方面,在肾髓质膜中,proANF1 - 30(Kd = 3.7 nM)和proANF31 - 67(Kd = 2.9 nM)的结合亲和力比ANF(Kd = 56 nM)高10倍。所有三种肽与近端小管的结合都非常弱,proANF1 - 30、proANF31 - 67和ANF各自的Kd分别为892、789和550 nM,表明它们对近端小管中结合位点的亲和力比对远曲小管中结合位点的亲和力低50至100倍(各自的Kd分别为4.9、5.3和11 nM)。每种肽在10^(-8)至10^(-11) M之间与各自的肾膜或小管结合,但仅在10^(-6)和10^(-7) M的浓度下才能与其他肽的受体结合。胰岛素、生长激素和促肾上腺皮质激素均未竞争性抑制proANF 1 - 30、proANF 31 - 67或ANF的结合。这些结果表明,proANF 1 - 30和proANF31 - 67并非通过ANF受体起作用,而是具有各自独立且不同的受体来介导它们在肾脏中的利尿和利钠作用。